医学
氟达拉滨
累积发病率
内科学
免疫抑制
移植
胃肠病学
造血干细胞移植
髓系白血病
随机对照试验
外科
环磷酰胺
白血病
化疗
作者
Dietger Niederwieser,Dirk Hasenclever,Wolfgang E. Berdel,Bart J. Biemond,Haifa Kathrin Al‐Ali,Yves Chalandon,Michel van Gelder,Christian Junghanß,Gösta Gahrton,Mathias Hänel,Rüdiger Hehlmann,Thomas Heinicke,Andreas Hochhaus,Simona Iacobelli,Rien van Marwijk Kooy,Nicolaus Kröger,Jeroen J.W.M. Janssen,Madlen Jentzsch,Frank Breywisch,Mohamad Mohty
出处
期刊:Haematologica
[Ferrata Storti Foundation]
日期:2024-08-08
卷期号:110 (1): 68-77
被引量:5
标识
DOI:10.3324/haematol.2024.285879
摘要
Given the selection of elderly patients with AML in first complete remission (CR1) the advantage of consolidation with allogeneic hematopoietic cell transplantation (HCT) over chemotherapy is still unclear. Newly diagnosed AML patients in CR1 aged 60-75 years were registered and a donor search initiated. After one consolidation cycle, patients with a matched donor were randomized to HCT with fludarabine/lowdose total body irradiation and cyclosporine/mycophenolate mofetil immunosuppression or conventional non-HCT. Primary outcome was restricted mean leukemia-free survival (RM-LFS) up to five years. Between 2010 and 2017, 245 patients (median age 67 years) were registered at CR1. After one consolidation, 26.9% of patients failed inclusion criteria. Of the 179 (73%) patients still on study, 75.4% had an HLA identical donor. Ten ineligible patients were excluded, and 125 randomized to HCT (n=83) or non-HCT (n=42). The primary outcome RM-LFS up to 5 years was 24.5 months (95%CI:18.9-30.1) in the HCT and 15.6 months (95%CI:10.4-20.8) in the non-HCT arm (p=0.022) due to a decrease in cumulative relapse incidence from 91.1 (95%CI:80.7-100.0) after non-HCT to 37.8 (95%CI:27.2-48.4)% after HCT (p
科研通智能强力驱动
Strongly Powered by AbleSci AI